Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 840 Memorial Dr CAMBRIDGE MA 02139-3789 |
Tel: | N/A |
Website: | https://www.mersana.com |
IR: | See website |
Key People | ||
Martin H. Huber President, Chief Executive Officer, Director | Brian Deschuytner Chief Financial Officer, Chief Operating Officer, Senior Vice President | Timothy B Lowinger Senior Vice President, Chief Science and Technology Officer |
Mohan Bala Senior Vice President, Chief Development Officer | Alejandra V. Carvajal Senior Vice President, Chief Legal Officer | Tushar Misra Senior Vice President, Chief Manufacturing Officer | Ashish Mandelia Chief Accounting Officer, Vice President |
Business Overview |
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. |
Financial Overview |
For the fiscal year ended 31 December 2023, Mersana Therapeutics Inc revenues increased 39% to $36.9M. Net loss decreased 16% to $171.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 15% to $137.2M (expense), Interest Income increase from $2.9M to $12.1M (income). |
Employees: | 123 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $205.73M as of Dec 31, 2023 |
Annual revenue (TTM): | $36.86M as of Dec 31, 2023 |
EBITDA (TTM): | -$169.44M as of Dec 31, 2023 |
Net annual income (TTM): | -$171.67M as of Dec 31, 2023 |
Free cash flow (TTM): | -$171.05M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 121,303,007 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |